肝移植：昨日、今日与明日。
Liver transplantation: yesterday, today and tomorrow.
作者信息
Abbasoglu Osman
出版信息
World J Gastroenterol. 2008 May 28;14(20):3117-22. doi: 10.3748/wjg.14.3117.
Abstract
With the advances in technical skills, management of postoperative complications and improvements in immunosuppressive drugs, liver transplantation is the standard treatment for many patients with chronic liver disease. Today, shortage of donor organs seems to be the major limiting factor for the application of liver transplantation. This review focuses on five issues that are challenging to clinical practice of liver transplantation and relevant to gastroenterologists. These include living donor liver transplantation, recurrent viral hepatitis, non-heart-beating donors, hepatocellular carcinoma, and ABO incompatible liver transplantation. Living donor and non-heart beating donor transplantations were initiated as a solution to increase the donor organ pool and it is expected that there will be an increase in the number of these donors. Recurrent hepatitis C and hepatocellular carcinoma following liver transplantation are among major problems and ongoing research in these diseases may lead to better outcomes in these recipients.
摘要
随着技术水平的进步、术后并发症管理的改善以及免疫抑制药物的发展，肝移植已成为许多慢性肝病患者的标准治疗方法。如今，供体器官短缺似乎是肝移植应用的主要限制因素。本综述聚焦于对肝移植临床实践具有挑战性且与胃肠病学家相关的五个问题。这些问题包括活体肝移植、复发性病毒性肝炎、非心脏跳动供体、肝细胞癌以及ABO血型不相容肝移植。活体供体和非心脏跳动供体移植最初是作为增加供体器官库的一种解决方案而开展的，预计这些供体的数量将会增加。肝移植后的复发性丙型肝炎和肝细胞癌是主要问题，对这些疾病的持续研究可能会使这些受者获得更好的治疗效果。
相似文献
1
Liver transplantation: yesterday, today and tomorrow.肝移植：昨日、今日与明日。
World J Gastroenterol. 2008 May 28;14(20):3117-22. doi: 10.3748/wjg.14.3117.
2
Long-term recurrence-free survival after liver transplantation from an ABO-incompatible living donor for treatment of hepatocellular carcinoma exceeding Milano criteria in a patient with hepatitis B virus cirrhosis: a case report.一名乙型肝炎病毒肝硬化患者接受 ABO 血型不相容活体供肝肝移植治疗超出米兰标准的肝细胞癌后的长期无复发生存：病例报告
Transplant Proc. 2012 Mar;44(2):565-9. doi: 10.1016/j.transproceed.2012.01.029.
3
Current concepts in transplant surgery: liver transplantation today.移植外科的当前概念：今日的肝移植
Langenbecks Arch Surg. 2008 May;393(3):245-60. doi: 10.1007/s00423-007-0262-6. Epub 2008 Feb 29.
4
[Living donor liver transplantation].[活体供肝肝移植]
Chirurg. 2003 Oct;74(10):944-50. doi: 10.1007/s00104-003-0744-1.
5
Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma.ABO 不相容成人活体肝移植治疗肝细胞癌患者的结局。
J Hepatol. 2018 Jun;68(6):1153-1162. doi: 10.1016/j.jhep.2018.02.002. Epub 2018 Feb 13.
6
ABO-incompatible adult living donor liver transplantation for hepatocellular carcinoma.ABO血型不相容的成人活体肝移植治疗肝细胞癌
Transplant Proc. 2008 Oct;40(8):2497-500. doi: 10.1016/j.transproceed.2008.07.054.
7
[Liver transplantation in Germany].[德国的肝移植]
Zentralbl Chir. 2003 Oct;128(10):831-41. doi: 10.1055/s-2003-44344.
8
ABO-incompatible Living Donor Liver Transplantation With Rituximab and Total Plasma Exchange Does Not Increase Hepatocellular Carcinoma Recurrence.ABO 不相容活体供肝移植联合利妥昔单抗和全血浆置换不会增加肝细胞癌复发。
Transplantation. 2018 Oct;102(10):1695-1701. doi: 10.1097/TP.0000000000002154.
9
Living donor liver transplantation for hepatitis C.丙型肝炎的活体供肝肝移植。
Surg Today. 2013 Jul;43(7):709-14. doi: 10.1007/s00595-012-0361-z. Epub 2012 Oct 6.
10
Challenges in living donor liver transplantation.活体供肝肝移植中的挑战。
Clin Liver Dis. 2014 Aug;18(3):651-60. doi: 10.1016/j.cld.2014.05.007.
引用本文的文献
1
New advances in the treatment of intermediate and advanced hepatocellular carcinoma.中晚期肝细胞癌治疗的新进展
Front Oncol. 2024 Sep 23;14:1430991. doi: 10.3389/fonc.2024.1430991. eCollection 2024.
2
Thrombocytopenia after liver transplantation: Should we care?肝移植后血小板减少症：我们应该关注吗？
World J Gastroenterol. 2018 Apr 7;24(13):1386-1397. doi: 10.3748/wjg.v24.i13.1386.
3
Vascular complications after adult living donor liver transplantation: Evaluation with ultrasonography.成人活体肝移植术后血管并发症：超声评估
World J Gastroenterol. 2016 Jan 28;22(4):1617-26. doi: 10.3748/wjg.v22.i4.1617.
4
Downregulation of Lung Toll-Like Receptor 4 Could Effectively Attenuate Liver Transplantation-Induced Pulmonary Damage at the Early Stage of Reperfusion.肺组织Toll样受体4的下调可有效减轻再灌注早期肝移植诱导的肺损伤。
Mediators Inflamm. 2015;2015:383907. doi: 10.1155/2015/383907. Epub 2015 Sep 29.
5
Q-FISH measurement of hepatocyte telomere lengths in donor liver and graft after pediatric living-donor liver transplantation: donor age affects telomere length sustainability.Q-FISH 检测小儿活体肝移植供肝及移植物肝细胞端粒长度：供者年龄影响端粒长度的稳定性。
PLoS One. 2014 Apr 11;9(4):e93749. doi: 10.1371/journal.pone.0093749. eCollection 2014.
6
Case report: living donor liver transplantation for giant hepatic hemangioma using a right lobe graft without the middle hepatic vein.病例报告：使用无肝中静脉的右叶移植物进行活体供肝肝移植治疗巨大肝血管瘤
World J Surg Oncol. 2014 Apr 4;12:83. doi: 10.1186/1477-7819-12-83.
7
Transfusion medicine and solid organ transplant - Update and review of some current issues.输血医学与实体器官移植——当前一些问题的更新与综述
Med J Armed Forces India. 2013 Apr;69(2):162-7. doi: 10.1016/j.mjafi.2012.11.012. Epub 2013 Feb 23.
8
Reversal of severe hepatopulmonary syndrome in chronic hepatic cirrhosis by living donor liver transplantation: report of two cases.活体肝移植治疗慢性肝硬变所致严重肝肺综合征两例报告
Surg Today. 2011 Mar;41(3):441-3. doi: 10.1007/s00595-009-4219-y. Epub 2011 Mar 2.
9
Risk factors for acute kidney injury following orthotopic liver transplantation: the impact of changes in renal function while patients await transplantation.原位肝移植术后急性肾损伤的危险因素：等待移植期间肾功能变化的影响。
BMC Nephrol. 2010 Nov 8;11:30. doi: 10.1186/1471-2369-11-30.
10
Inhibition of ATIR by shRNA prevents collagen synthesis in hepatic stellate cells.shRNA 抑制 ATIR 可防止肝星状细胞胶原合成。
Mol Cell Biochem. 2010 Nov;344(1-2):195-202. doi: 10.1007/s11010-010-0542-2. Epub 2010 Aug 12.
本文引用的文献
1
Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation.米兰标准以外的肝细胞癌的外科治疗。肝切除、挽救性移植和原位肝移植的结果。
Ann Surg Oncol. 2008 May;15(5):1383-91. doi: 10.1245/s10434-008-9851-z. Epub 2008 Mar 5.
2
Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: pilot study.肝移植后复发性丙型肝炎的干扰素和利巴韦林抗病毒维持治疗：初步研究。
J Gastroenterol Hepatol. 2007 Dec;22(12):2135-42. doi: 10.1111/j.1440-1746.2006.04516.x.
3
Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation.肝移植后复发性病毒性肝炎的预防和治疗。
Nephrol Dial Transplant. 2007 Sep;22 Suppl 8:viii37-viii46. doi: 10.1093/ndt/gfm655.
4
Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.拉米夫定联合小剂量乙型肝炎免疫球蛋白预防肝移植后乙型肝炎复发
Gastroenterology. 2007 Mar;132(3):931-7. doi: 10.1053/j.gastro.2007.01.005. Epub 2007 Jan 5.
5
Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation.肝移植后，短期大剂量随后长期小剂量使用乙肝免疫球蛋白和拉米夫定治疗可预防乙肝复发。
Transplantation. 2007 Jan 27;83(2):231-3. doi: 10.1097/01.tp.0000246310.75638.86.
6
Liver resection and transplantation in the management of hepatocellular carcinoma: a review.肝细胞癌治疗中肝切除与肝移植的综述
Exp Clin Transplant. 2006 Dec;4(2):549-58.
7
Prevention of hepatitis B virus recurrence after liver transplantation.肝移植后乙肝病毒复发的预防
Clin Transplant. 2006;20 Suppl 17:111-6. doi: 10.1111/j.1399-0012.2006.00609.x.
8
Successful ABO-incompatible liver transplantation using A2 donors.
Transplant Proc. 2006 Oct;38(8):2667-70. doi: 10.1016/j.transproceed.2006.07.025.
9
Early recurrence of hepatitis C virus infection after liver transplantation.肝移植后丙型肝炎病毒感染的早期复发
Liver Transpl. 2006 Nov;12(11 Suppl 2):S32-7. doi: 10.1002/lt.20942.
10
Living-donor liver transplantation for hepatocellular carcinoma.
J Hepatobiliary Pancreat Surg. 2006;13(5):393-7. doi: 10.1007/s00534-005-1079-8.
Zotero 插件